UChicago Medicine has started an investigator-initiated first-in-human trial of an on-site manufactured T-cell receptor therapy targeting NY-ESO-1 in patients with advanced solid tumors. The approach is designed to resist TGF-beta suppression, aiming to improve persistence and activity of the engineered T cells in the immunosuppressive tumor microenvironment. The study highlights a manufacturing shift toward fully site-based production for cell therapies, potentially tightening turnaround times and enabling individualized engineering. For solid tumors where standard CAR-T-like strategies have struggled with antigen selection and immune suppression, targeting NY-ESO-1 plus microenvironmental resistance is a notable translational step. Clinicians will monitor safety and early signals of efficacy while assessing how the engineered T cells perform in vivo under TGF-beta pressure—an axis increasingly recognized as a key barrier to therapeutic durability.